Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options

Biotech & MedTech, Critical Minerals & Rare Earths

March 26, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Company“), announces that it has filed its annual audited financial statements and management’s discussion and analysis for the year ended November 30, 2023 on SEDAR+.

Option Grant

Voyageur also announces that it has granted 3,700,000 stock options (the ” Options “) to directors, officers and consultants of the Company pursuant to its incentive stock option plan. On March 26, 2024, the Board approved the grant of Options, to be effective on March 26, 2024, with an exercise price equal to that of the closing price on that day of $0.07 cents per share. The Options were issued with 3,400,000 options vesting 12 months from the date of issue and having a 5-year term, and the remaining 300,000 options vesting immediately and having a 10-year term.  The Options are subject to regulatory and TSX Venture Exchange approval.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium, iodine and carbon Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium, iodine and carbon contrast imaging market, Voyageur aims to become a key player by producing its own barium, iodine, and fullerene minerals.

Voyageur’s business plan is set to generate cash flow by partnering with established third party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. Voyageur is forming partnerships with distribution companies in Canada and globally, who will sell Voyageur’s products to their existing markets. As the Company solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, utilizing the Frances Creek barium sulfate to further expand its revenue streams at higher profit margins. Voyageur is committed to sustainability and environmental stewardship. The Company envisions a future where carbon neutrality is the norm, and to achieve this, it plans to build state-of-the-art carbon-neutral infrastructure. By investing in carbon neutral energy sources and sustainable manufacturing practices, it aims to become 100% carbon neutral across all its manufacturing activities. Voyageur’s commitment to the environment sets it apart as a pioneer in the industry.

At the core of the Company’s operations, Voyageur owns a 100% interest in a barium sulphate (barite) project, the Frances Creek property. Additionally, Voyageur holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, USA, further bolstering its position in the industry. Voyageur also owns a 100% interest in two battery mineral projects which focus on copper/zinc development.

Voyageur’s ambitious vision is to become the first vertically integrated, carbon-neutral company in the imaging contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, it plans to ensure unmatched quality and cost efficiency. Voyageur embodies the motto of “From the Earth to the Bottle,” highlighting its commitment to responsible sourcing and manufacturing practices.

For Further Information:

Brent Willis, CEOAlbert Deslauriers, CFO
[email protected] or 403-923-5944[email protected]
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking” Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to regulatory and TSXV approval of the Options, and Voyageur’s plans to become self sufficient and vertically integrated, and other statements herein, which expressly or impliedly speak to Voyageur’s expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur’s products, and general risks relating to Voyageur’s business. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR+ website at Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.

Voyageur Pharmaceuticals Ltd.

Voyageur Pharmaceuticals Ltd. (TSXV: VM), a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium, iodine and carbon Active…

Leave a Reply

Your email address will not be published. Required fields are marked *